Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries.
| Autor: | Erwin De Cock, Persefoni Kritikou, Mariana Sandoval, Sunning Tao, Christof Wiesner, Angelo Michele Carella, Charles Ngoh, Tim Waterboer |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: | |
| Zdroj: | PLoS ONE, Vol 11, Iss 6, p e0157957 (2016) |
| Druh dokumentu: | article |
| ISSN: | 1932-6203 19144288 |
| DOI: | 10.1371/journal.pone.0157957 |
| Popis: | Rituximab is a standard treatment for non-Hodgkin lymphoma. The SABRINA trial (NCT01200758) showed that a subcutaneous (SC) rituximab formulation did not compromise efficacy or safety compared with intravenous (IV) infusion. We aimed to quantify active healthcare professional (HCP) time and patient chair time for rituximab SC and IV, including potential time savings.This non-interventional time and motion study was run in eight countries and 30 day oncology units. Rituximab SC data were collected alongside the MabCute trial (NCT01461928); IV data were collected per routine real-world practice. Trained observers recorded active HCP time for pre-specified tasks (stopwatch) and chair time (time of day). A random intercept model was used to analyze active HCP time (by task and for all tasks combined) in the treatment room and drug preparation area, drug administration duration, chair time and patient treatment room time by country and/or across countries. Active HCP and chair time were extrapolated to a patient's first year of treatment (11 rituximab sessions).Mean active HCP time was 35.0 and 23.7 minutes for IV and SC process, respectively (-32%, p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|